CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin

Daiichi Sankyo

Status and phase: Terminated; Phase 2

Conditions: Metastatic Colorectal Cancer

Treatments: Drug: irinotecan; Drug: CS-1008

Study type: Interventional

Funder types: Industry

Identifiers

NCT00969033

CS1008-A-E203

Details and patient eligibility

About

The purpose of this study is to determine the effect of CS-1008 in combination with irinotecan compared to irinotecan alone on Progression-Free Survival (PFS) in subjects with metastatic or advanced colorectal cancer (CRC) who have failed oxaliplatin-based first-line treatment.

Enrollment: 8 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed CRC which is now metastatic and after failure of oxaliplatin-based first-line treatment.

• At least 18 years of age.

• ECOG performance status =< 1.

• Measurable disease based on RECIST criteria.

• Adequate organ and bone marrow function as evidenced by:

  • Hemoglobin >= 9.0 g/dL (may be transfused to this level)
  • Absolute neutrophil count (ANC) >= 1.5 x 109/L
  • Platelet count >= 100 x 109/L
  • Serum creatinine =< upper limit of normal (ULN) or creatinine clearance > 50 mL/min
  • AST <= 2.5 x ULN in subjects with no liver metastasis and <= 5.0 x ULN in subjects with liver metastasis
  • Total bilirubin < 1.5 x ULN

• Men and women of childbearing potential must be willing to consent to using effective contraception (e.g., hormonal contraceptives, bilateral tubal ligation, barrier with spermicide, intrauterine device) while on treatment and for 3 months thereafter.

• All female subjects of childbearing potential must have a negative pregnancy test (serum or urine) result within 7 days before initiating study treatment.

• Subjects must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an IEC/IRB approved ICF before performance of any study specific procedures or tests.

• Subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

• Anticipation of need for a major surgical procedure or radiotherapy (RT) during the study.

• Treatment with chemotherapy hormonal therapy, RT, minor surgery, or any investigational agent within 4 weeks before study enrollment. Treatment with nitrosoureas, mitomycin C, immunotherapy, biological therapy, or major surgery within six weeks prior to study enrollment. St John's Wort within 2 weeks prior to study enrollment or during the study.

• History of any of the following conditions within 6 months before study enrollment:

  • Clinically significant myocardial infarction or severe/unstable angina pectoris
  • New York Heart Association (NYHA) class III or IV congestive heart failure (Section 17.2)
  • Clinically significant cerebrovascular accident, transient ischemic attack or pulmonary embolism- Clinically significant pulmonary disease (e.g., severe chronic obstructive pulmonary disease or asthma)

• Presence of any of the following: Symptomatic brain metastasis; an uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis.

• Clinically significant active infection that requires antibiotic therapy or Human Immunodeficiency Virus (HIV) positive subjects receiving antiretroviral therapy.

• History of malignancy other than CRC, unless there is the expectation that the malignancy has been cured, and tumor specific treatment for the malignancy has not been administered within the previous 5 years. Exceptions to this are non melanotic cancer of the skin and adequately treated carcinoma of the cervix-in-situ.

• Previous treatment with CS 1008, other agonistic DR5 antibody agents, or TRAIL agents.

• History of active chronic inflammatory bowel disease and/or bowel obstruction within the last 3 months.

• Pregnant or breast feeding.

• Known history of hypersensitivity reactions to irinotecan or to one of the excipients.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

8 participants in 2 patient groups

CS-1008 with irinotecan

Experimental group

Description:

CS-1008 and irinotecan

Treatment:

Drug: CS-1008

Drug: irinotecan

irintoecan

Active Comparator group

Description:

irinotecan alone

Treatment:

Drug: irinotecan